APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peptide-Based Vaccines for Cancer

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Peptide-Based Vaccines for Cancer Industry Growth and Trends Forecast to 2032

29 December 2025103 pages

Choose your research edition.

Industry ResearchPeptide-Based Vaccines for Cancer Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide-Based Vaccines for Cancer Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Peptide-Based Vaccines for Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide-Based Vaccines for Cancer Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide-Based Vaccines for Cancer Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Peptide-Based Vaccines for Cancer market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Peptide-Based Vaccines for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Peptide-Based Vaccines for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Peptide-Based Vaccines for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Peptide-Based Vaccines for Cancer include ACT, Almac, AmbioPharm, Anergis, Immatics, Immatics, Marker Therapeutics, Inc., OncoPep and Sellas Life Sciences, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Peptide-Based Vaccines for Cancer market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Peptide-Based Vaccines for Cancer market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Peptide-Based Vaccines for Cancer market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Peptide-Based Vaccines for Cancer.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Peptide-Based Vaccines for Cancer market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Peptide-Based Vaccines for Cancer Market by Company

ACT

Almac

AmbioPharm

Anergis

Immatics

Immatics

Marker Therapeutics, Inc.

OncoPep

Sellas Life Sciences

Ultimovacs

Peptide-Based Vaccines for Cancer Segment by Type

Synthetic Polypeptide Vaccines

Recombinant Polypeptide Vaccine

Other

Peptide-Based Vaccines for Cancer Segment by Application

Infectious Disease Prevention

Cancer Immunotherapy

Other

Peptide-Based Vaccines for Cancer Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide-Based Vaccines for Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide-Based Vaccines for Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide-Based Vaccines for Cancer.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Peptide-Based Vaccines for Cancer manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Peptide-Based Vaccines for Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Synthetic Polypeptide Vaccines Table 2. Major Company of Recombinant Polypeptide Vaccine Table 3. Major Company of Other Table 4. Global Peptide-Based Vaccines for Cancer Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Peptide-Based Vaccines for Cancer Sales by Type (2021-2026) & (K Units) Table 6. Global Peptide-Based Vaccines for Cancer Sales Market Share in Volume by Type (2021-2026) Table 7. Global Peptide-Based Vaccines for Cancer Sales by Type (2021-2026) & (US$ Million) Table 8. Global Peptide-Based Vaccines for Cancer Sales Market Share in Value by Type (2021-2026) Table 9. Global Peptide-Based Vaccines for Cancer Price by Type (2021-2026) & (US$/Unit) Table 10. Global Peptide-Based Vaccines for Cancer Sales by Type (2027-2032) & (K Units) Table 11. Global Peptide-Based Vaccines for Cancer Sales Market Share in Volume by Type (2027-2032) Table 12. Global Peptide-Based Vaccines for Cancer Sales by Type (2027-2032) & (US$ Million) Table 13. Global Peptide-Based Vaccines for Cancer Sales Market Share in Value by Type (2027-2032) Table 14. Global Peptide-Based Vaccines for Cancer Price by Type (2027-2032) & (US$/Unit) Table 15. North America Peptide-Based Vaccines for Cancer Sales by Type (2021-2026) & (K Units) Table 16. North America Peptide-Based Vaccines for Cancer Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Peptide-Based Vaccines for Cancer Sales by Type (2021-2026) & (K Units) Table 18. Europe Peptide-Based Vaccines for Cancer Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Peptide-Based Vaccines for Cancer Sales by Type (2021-2026) & (K Units) Table 20. Asia-Pacific Peptide-Based Vaccines for Cancer Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Peptide-Based Vaccines for Cancer Sales by Type (2021-2026) & (K Units) Table 22. Latin America Peptide-Based Vaccines for Cancer Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Peptide-Based Vaccines for Cancer Sales by Type (2021-2026) & (K Units) Table 24. Middle East and Africa Peptide-Based Vaccines for Cancer Sales by Type (2021-2026) & (US$ Million) Table 25. Peptide-Based Vaccines for Cancer Industry Trends Table 26. Peptide-Based Vaccines for Cancer Industry Drivers Table 27. Peptide-Based Vaccines for Cancer Industry Opportunities and Challenges Table 28. Peptide-Based Vaccines for Cancer Industry Restraints Table 29. Global Peptide-Based Vaccines for Cancer Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Peptide-Based Vaccines for Cancer Revenue Market Share by Company (2021-2026) Table 31. Global Peptide-Based Vaccines for Cancer Sales by Company (2021-2026) & (K Units) Table 32. Global Peptide-Based Vaccines for Cancer Sales Share by Company (2021-2026) Table 33. Global Peptide-Based Vaccines for Cancer Market Price by Company (2021-2026) & (US$/Unit) Table 34. Global Peptide-Based Vaccines for Cancer Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Peptide-Based Vaccines for Cancer Major Company Production Sites and Headquarters Table 36. Global Peptide-Based Vaccines for Cancer Company, Product Type & Application Table 37. Global Peptide-Based Vaccines for Cancer Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Peptide-Based Vaccines for Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Peptide-Based Vaccines for Cancer Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Peptide-Based Vaccines for Cancer Sales by Region (2021-2026) & (K Units) Table 42. Global Peptide-Based Vaccines for Cancer Sales Market Share in Volume by Region (2021-2026) Table 43. Global Peptide-Based Vaccines for Cancer Sales by Region (2021-2026) & (US$ Million) Table 44. Global Peptide-Based Vaccines for Cancer Sales Market Share in Value by Region (2021-2026) Table 45. Global Peptide-Based Vaccines for Cancer Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Global Peptide-Based Vaccines for Cancer Sales by Region (2027-2032) & (K Units) Table 47. Global Peptide-Based Vaccines for Cancer Sales Market Share in Volume by Region (2027-2032) Table 48. Global Peptide-Based Vaccines for Cancer Sales by Region (2027-2032) & (US$ Million) Table 49. Global Peptide-Based Vaccines for Cancer Sales Market Share in Value by Region (2027-2032) Table 50. Global Peptide-Based Vaccines for Cancer Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 51. Global Peptide-Based Vaccines for Cancer Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Peptide-Based Vaccines for Cancer Sales by Application (2021-2026) & (K Units) Table 53. Global Peptide-Based Vaccines for Cancer Sales Market Share in Volume by Application (2021-2026) Table 54. Global Peptide-Based Vaccines for Cancer Sales by Application (2021-2026) & (US$ Million) Table 55. Global Peptide-Based Vaccines for Cancer Sales Market Share in Value by Application (2021-2026) Table 56. Global Peptide-Based Vaccines for Cancer Price by Application (2021-2026) & (US$/Unit) Table 57. Global Peptide-Based Vaccines for Cancer Sales by Application (2027-2032) & (K Units) Table 58. Global Peptide-Based Vaccines for Cancer Sales Market Share in Volume by Application (2027-2032) Table 59. Global Peptide-Based Vaccines for Cancer Sales by Application (2027-2032) & (US$ Million) Table 60. Global Peptide-Based Vaccines for Cancer Sales Market Share in Value by Application (2027-2032) Table 61. Global Peptide-Based Vaccines for Cancer Price by Application (2027-2032) & (US$/Unit) Table 62. North America Peptide-Based Vaccines for Cancer Sales by Application (2021-2026) & (K Units) Table 63. North America Peptide-Based Vaccines for Cancer Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Peptide-Based Vaccines for Cancer Sales by Application (2021-2026) & (K Units) Table 65. Europe Peptide-Based Vaccines for Cancer Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Peptide-Based Vaccines for Cancer Sales by Application (2021-2026) & (K Units) Table 67. Asia-Pacific Peptide-Based Vaccines for Cancer Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Peptide-Based Vaccines for Cancer Sales by Application (2021-2026) & (K Units) Table 69. Latin America Peptide-Based Vaccines for Cancer Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Peptide-Based Vaccines for Cancer Sales by Application (2021-2026) & (K Units) Table 71. Middle East and Africa Peptide-Based Vaccines for Cancer Sales by Application (2021-2026) & (US$ Million) Table 72. ACT Company Information Table 73. ACT Business Overview Table 74. ACT Peptide-Based Vaccines for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. ACT Peptide-Based Vaccines for Cancer Product Portfolio Table 76. ACT Recent Development Table 77. Almac Company Information Table 78. Almac Business Overview Table 79. Almac Peptide-Based Vaccines for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Almac Peptide-Based Vaccines for Cancer Product Portfolio Table 81. Almac Recent Development Table 82. AmbioPharm Company Information Table 83. AmbioPharm Business Overview Table 84. AmbioPharm Peptide-Based Vaccines for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. AmbioPharm Peptide-Based Vaccines for Cancer Product Portfolio Table 86. AmbioPharm Recent Development Table 87. Anergis Company Information Table 88. Anergis Business Overview Table 89. Anergis Peptide-Based Vaccines for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Anergis Peptide-Based Vaccines for Cancer Product Portfolio Table 91. Anergis Recent Development Table 92. Immatics Company Information Table 93. Immatics Business Overview Table 94. Immatics Peptide-Based Vaccines for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Immatics Peptide-Based Vaccines for Cancer Product Portfolio Table 96. Immatics Recent Development Table 97. Immatics Company Information Table 98. Immatics Business Overview Table 99. Immatics Peptide-Based Vaccines for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Immatics Peptide-Based Vaccines for Cancer Product Portfolio Table 101. Immatics Recent Development Table 102. Marker Therapeutics, Inc. Company Information Table 103. Marker Therapeutics, Inc. Business Overview Table 104. Marker Therapeutics, Inc. Peptide-Based Vaccines for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Marker Therapeutics, Inc. Peptide-Based Vaccines for Cancer Product Portfolio Table 106. Marker Therapeutics, Inc. Recent Development Table 107. OncoPep Company Information Table 108. OncoPep Business Overview Table 109. OncoPep Peptide-Based Vaccines for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. OncoPep Peptide-Based Vaccines for Cancer Product Portfolio Table 111. OncoPep Recent Development Table 112. Sellas Life Sciences Company Information Table 113. Sellas Life Sciences Business Overview Table 114. Sellas Life Sciences Peptide-Based Vaccines for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Sellas Life Sciences Peptide-Based Vaccines for Cancer Product Portfolio Table 116. Sellas Life Sciences Recent Development Table 117. Ultimovacs Company Information Table 118. Ultimovacs Business Overview Table 119. Ultimovacs Peptide-Based Vaccines for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Ultimovacs Peptide-Based Vaccines for Cancer Product Portfolio Table 121. Ultimovacs Recent Development Table 122. North America Peptide-Based Vaccines for Cancer Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 123. North America Peptide-Based Vaccines for Cancer Sales by Country (2021-2026) & (K Units) Table 124. North America Peptide-Based Vaccines for Cancer Sales Market Share by Country (2021-2026) Table 125. North America Peptide-Based Vaccines for Cancer Sales Forecast by Country (2027-2032) & (K Units) Table 126. North America Peptide-Based Vaccines for Cancer Sales Market Share Forecast by Country (2027-2032) Table 127. North America Peptide-Based Vaccines for Cancer Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 128. North America Peptide-Based Vaccines for Cancer Market Size by Country (2021-2026) & (US$ Million) Table 129. North America Peptide-Based Vaccines for Cancer Market Share by Country (2021-2026) Table 130. North America Peptide-Based Vaccines for Cancer Market Size Forecast by Country (2027-2032) & (US$ Million) Table 131. North America Peptide-Based Vaccines for Cancer Market Share Forecast by Country (2027-2032) Table 132. Europe Peptide-Based Vaccines for Cancer Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 133. Europe Peptide-Based Vaccines for Cancer Sales by Country (2021-2026) & (K Units) Table 134. Europe Peptide-Based Vaccines for Cancer Sales Market Share by Country (2021-2026) Table 135. Europe Peptide-Based Vaccines for Cancer Sales Forecast by Country (2027-2032) & (K Units) Table 136. Europe Peptide-Based Vaccines for Cancer Sales Market Share Forecast by Country (2027-2032) Table 137. Europe Peptide-Based Vaccines for Cancer Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 138. Europe Peptide-Based Vaccines for Cancer Market Size by Country (2021-2026) & (US$ Million) Table 139. Europe Peptide-Based Vaccines for Cancer Market Share by Country (2021-2026) Table 140. Europe Peptide-Based Vaccines for Cancer Market Size Forecast by Country (2027-2032) & (US$ Million) Table 141. Europe Peptide-Based Vaccines for Cancer Market Share Forecast by Country (2027-2032) Table 142. Asia-Pacific Peptide-Based Vaccines for Cancer Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 143. Asia-Pacific Peptide-Based Vaccines for Cancer Sales by Country (2021-2026) & (K Units) Table 144. Asia-Pacific Peptide-Based Vaccines for Cancer Sales Market Share by Country (2021-2026) Table 145. Asia-Pacific Peptide-Based Vaccines for Cancer Sales Forecast by Country (2027-2032) & (K Units) Table 146. Asia-Pacific Peptide-Based Vaccines for Cancer Sales Market Share Forecast by Country (2027-2032) Table 147. Asia-Pacific Peptide-Based Vaccines for Cancer Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 148. Asia-Pacific Peptide-Based Vaccines for Cancer Market Size by Country (2021-2026) & (US$ Million) Table 149. Asia-Pacific Peptide-Based Vaccines for Cancer Market Share by Country (2021-2026) Table 150. Asia-Pacific Peptide-Based Vaccines for Cancer Market Size Forecast by Country (2027-2032) & (US$ Million) Table 151. Asia-Pacific Peptide-Based Vaccines for Cancer Market Share Forecast by Country (2027-2032) Table 152. Latin America Peptide-Based Vaccines for Cancer Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 153. Latin America Peptide-Based Vaccines for Cancer Sales by Country (2021-2026) & (K Units) Table 154. Latin America Peptide-Based Vaccines for Cancer Sales Market Share by Country (2021-2026) Table 155. Latin America Peptide-Based Vaccines for Cancer Sales Forecast by Country (2027-2032) & (K Units) Table 156. Latin America Peptide-Based Vaccines for Cancer Sales Market Share Forecast by Country (2027-2032) Table 157. Latin America Peptide-Based Vaccines for Cancer Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 158. Latin America Peptide-Based Vaccines for Cancer Market Size by Country (2021-2026) & (US$ Million) Table 159. Latin America Peptide-Based Vaccines for Cancer Market Share by Country (2021-2026) Table 160. Latin America Peptide-Based Vaccines for Cancer Market Size Forecast by Country (2027-2032) & (US$ Million) Table 161. Latin America Peptide-Based Vaccines for Cancer Market Share Forecast by Country (2027-2032) Table 162. Middle East and Africa Peptide-Based Vaccines for Cancer Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 163. Middle East and Africa Peptide-Based Vaccines for Cancer Sales by Country (2021-2026) & (K Units) Table 164. Middle East and Africa Peptide-Based Vaccines for Cancer Sales Market Share by Country (2021-2026) Table 165. Middle East and Africa Peptide-Based Vaccines for Cancer Sales Forecast by Country (2027-2032) & (K Units) Table 166. Middle East and Africa Peptide-Based Vaccines for Cancer Sales Market Share Forecast by Country (2027-2032) Table 167. Middle East and Africa Peptide-Based Vaccines for Cancer Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 168. Middle East and Africa Peptide-Based Vaccines for Cancer Market Size by Country (2021-2026) & (US$ Million) Table 169. Middle East and Africa Peptide-Based Vaccines for Cancer Market Share by Country (2021-2026) Table 170. Middle East and Africa Peptide-Based Vaccines for Cancer Market Size Forecast by Country (2027-2032) & (US$ Million) Table 171. Middle East and Africa Peptide-Based Vaccines for Cancer Market Share Forecast by Country (2027-2032) Table 172. Key Raw Materials Table 173. Raw Materials Key Suppliers Table 174. Peptide-Based Vaccines for Cancer Distributors List Table 175. Peptide-Based Vaccines for Cancer Customers List Table 176. Research Programs/Design for This Report Table 177. Authors List of This Report Table 178. Secondary Sources Table 179. Primary Sources List of Figures Figure 1. Peptide-Based Vaccines for Cancer Image Figure 2. Global Peptide-Based Vaccines for Cancer Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide-Based Vaccines for Cancer Market Size (2021-2032) & (US$ Million) Figure 4. Global Peptide-Based Vaccines for Cancer Sales (2021-2032) & (K Units) Figure 5. Synthetic Polypeptide Vaccines Image Figure 6. Global Synthetic Polypeptide Vaccines Sales YoY Growth (2021-2032) & (K Units) Figure 7. Recombinant Polypeptide Vaccine Image Figure 8. Global Recombinant Polypeptide Vaccine Sales YoY Growth (2021-2032) & (K Units) Figure 9. Other Image Figure 10. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 11. Global Peptide-Based Vaccines for Cancer Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Peptide-Based Vaccines for Cancer Market Share by Type 2025 VS 2032 Figure 13. North America Peptide-Based Vaccines for Cancer Sales Market Share in Volume by Type in 2025 Figure 14. North America Peptide-Based Vaccines for Cancer Sales Market Share in Value by Type in 2025 Figure 15. Europe Peptide-Based Vaccines for Cancer Sales Market Share in Volume by Type in 2025 Figure 16. Europe Peptide-Based Vaccines for Cancer Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Peptide-Based Vaccines for Cancer Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Peptide-Based Vaccines for Cancer Sales Market Share in Value by Type in 2025 Figure 19. Latin America Peptide-Based Vaccines for Cancer Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Peptide-Based Vaccines for Cancer Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Peptide-Based Vaccines for Cancer Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Peptide-Based Vaccines for Cancer Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Peptide-Based Vaccines for Cancer Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Infectious Disease Prevention Image Figure 26. Global Infectious Disease Prevention Sales YoY Growth (2021-2032) & (K Units) Figure 27. Cancer Immunotherapy Image Figure 28. Global Cancer Immunotherapy Sales YoY Growth (2021-2032) & (K Units) Figure 29. Other Image Figure 30. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 31. Global Peptide-Based Vaccines for Cancer Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Peptide-Based Vaccines for Cancer Market Share by Application 2025 VS 2032 Figure 33. North America Peptide-Based Vaccines for Cancer Sales Market Share in Volume by Application in 2025 Figure 34. North America Peptide-Based Vaccines for Cancer Sales Market Share in Value by Application in 2025 Figure 35. Europe Peptide-Based Vaccines for Cancer Sales Market Share in Volume by Application in 2025 Figure 36. Europe Peptide-Based Vaccines for Cancer Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Peptide-Based Vaccines for Cancer Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Peptide-Based Vaccines for Cancer Sales Market Share in Value by Application in 2025 Figure 39. Latin America Peptide-Based Vaccines for Cancer Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Peptide-Based Vaccines for Cancer Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Peptide-Based Vaccines for Cancer Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Peptide-Based Vaccines for Cancer Sales Market Share in Value by Application in 2025 Figure 43. North America Peptide-Based Vaccines for Cancer Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 44. North America Peptide-Based Vaccines for Cancer Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Peptide-Based Vaccines for Cancer Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Peptide-Based Vaccines for Cancer Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Peptide-Based Vaccines for Cancer Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. Europe Peptide-Based Vaccines for Cancer Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Peptide-Based Vaccines for Cancer Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Peptide-Based Vaccines for Cancer Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Peptide-Based Vaccines for Cancer Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Asia-Pacific Peptide-Based Vaccines for Cancer Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Peptide-Based Vaccines for Cancer Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Peptide-Based Vaccines for Cancer Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Peptide-Based Vaccines for Cancer Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Latin America Peptide-Based Vaccines for Cancer Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Peptide-Based Vaccines for Cancer Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Peptide-Based Vaccines for Cancer Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Peptide-Based Vaccines for Cancer Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Middle East and Africa Peptide-Based Vaccines for Cancer Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Peptide-Based Vaccines for Cancer Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Peptide-Based Vaccines for Cancer Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Peptide-Based Vaccines for Cancer Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Peptide-Based Vaccines for Cancer Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Synthetic Polypeptide Vaccines
  • Recombinant Polypeptide Vaccine
  • Other
Applications
  • Infectious Disease Prevention
  • Cancer Immunotherapy
  • Other
Companies covered
  • ACT
  • Almac
  • AmbioPharm
  • Anergis
  • Immatics
  • Immatics
  • Marker Therapeutics, Inc.
  • OncoPep
  • Sellas Life Sciences
  • Ultimovacs

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Peptide-Based Vaccines for Cancer Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Peptide-Based Vaccines for Cancer Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Peptide-Based Vaccines for Cancer Market by Type
  6. 1.3.1 Synthetic Polypeptide Vaccines
  7. 1.3.2 Recombinant Polypeptide Vaccine
  8. 1.3.3 Other
  9. 1.4 Global Peptide-Based Vaccines for Cancer Market Size by Type
  10. 1.4.1 Global Peptide-Based Vaccines for Cancer Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Peptide-Based Vaccines for Cancer Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Peptide-Based Vaccines for Cancer Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Peptide-Based Vaccines for Cancer Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Peptide-Based Vaccines for Cancer Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Peptide-Based Vaccines for Cancer Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Peptide-Based Vaccines for Cancer Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Peptide-Based Vaccines for Cancer Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Peptide-Based Vaccines for Cancer Industry Trends
  2. 2.2 Peptide-Based Vaccines for Cancer Industry Drivers
  3. 2.3 Peptide-Based Vaccines for Cancer Industry Opportunities and Challenges
  4. 2.4 Peptide-Based Vaccines for Cancer Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Peptide-Based Vaccines for Cancer Revenue (2021-2026)
  2. 3.2 Global Top Players by Peptide-Based Vaccines for Cancer Sales (2021-2026)
  3. 3.3 Global Top Players by Peptide-Based Vaccines for Cancer Price (2021-2026)
  4. 3.4 Global Peptide-Based Vaccines for Cancer Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Peptide-Based Vaccines for Cancer Major Company Production Sites & Headquarters
  6. 3.6 Global Peptide-Based Vaccines for Cancer Company, Product Type & Application
  7. 3.7 Global Peptide-Based Vaccines for Cancer Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Peptide-Based Vaccines for Cancer Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Peptide-Based Vaccines for Cancer Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Peptide-Based Vaccines for Cancer Tier 1, Tier 2, and Tier 3
4 Peptide-Based Vaccines for Cancer Regional Status and Outlook
  1. 4.1 Global Peptide-Based Vaccines for Cancer Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Peptide-Based Vaccines for Cancer Historic Market Size by Region
  3. 4.2.1 Global Peptide-Based Vaccines for Cancer Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Peptide-Based Vaccines for Cancer Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Peptide-Based Vaccines for Cancer Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Peptide-Based Vaccines for Cancer Forecasted Market Size by Region
  7. 4.3.1 Global Peptide-Based Vaccines for Cancer Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Peptide-Based Vaccines for Cancer Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Peptide-Based Vaccines for Cancer Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Peptide-Based Vaccines for Cancer by Application
  1. 5.1 Peptide-Based Vaccines for Cancer Market by Application
  2. 5.1.1 Infectious Disease Prevention
  3. 5.1.2 Cancer Immunotherapy
  4. 5.1.3 Other
  5. 5.2 Global Peptide-Based Vaccines for Cancer Market Size by Application
  6. 5.2.1 Global Peptide-Based Vaccines for Cancer Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Peptide-Based Vaccines for Cancer Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Peptide-Based Vaccines for Cancer Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Peptide-Based Vaccines for Cancer Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Peptide-Based Vaccines for Cancer Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Peptide-Based Vaccines for Cancer Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Peptide-Based Vaccines for Cancer Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Peptide-Based Vaccines for Cancer Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 ACT
  2. 6.1.1 ACT Company Information
  3. 6.1.2 ACT Business Overview
  4. 6.1.3 ACT Peptide-Based Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 ACT Peptide-Based Vaccines for Cancer Product Portfolio
  6. 6.1.5 ACT Recent Developments
  7. 6.2 Almac
  8. 6.2.1 Almac Company Information
  9. 6.2.2 Almac Business Overview
  10. 6.2.3 Almac Peptide-Based Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Almac Peptide-Based Vaccines for Cancer Product Portfolio
  12. 6.2.5 Almac Recent Developments
  13. 6.3 AmbioPharm
  14. 6.3.1 AmbioPharm Company Information
  15. 6.3.2 AmbioPharm Business Overview
  16. 6.3.3 AmbioPharm Peptide-Based Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 AmbioPharm Peptide-Based Vaccines for Cancer Product Portfolio
  18. 6.3.5 AmbioPharm Recent Developments
  19. 6.4 Anergis
  20. 6.4.1 Anergis Company Information
  21. 6.4.2 Anergis Business Overview
  22. 6.4.3 Anergis Peptide-Based Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Anergis Peptide-Based Vaccines for Cancer Product Portfolio
  24. 6.4.5 Anergis Recent Developments
  25. 6.5 Immatics
  26. 6.5.1 Immatics Company Information
  27. 6.5.2 Immatics Business Overview
  28. 6.5.3 Immatics Peptide-Based Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Immatics Peptide-Based Vaccines for Cancer Product Portfolio
  30. 6.5.5 Immatics Recent Developments
  31. 6.6 Immatics
  32. 6.6.1 Immatics Company Information
  33. 6.6.2 Immatics Business Overview
  34. 6.6.3 Immatics Peptide-Based Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Immatics Peptide-Based Vaccines for Cancer Product Portfolio
  36. 6.6.5 Immatics Recent Developments
  37. 6.7 Marker Therapeutics, Inc.
  38. 6.7.1 Marker Therapeutics, Inc. Company Information
  39. 6.7.2 Marker Therapeutics, Inc. Business Overview
  40. 6.7.3 Marker Therapeutics, Inc. Peptide-Based Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Marker Therapeutics, Inc. Peptide-Based Vaccines for Cancer Product Portfolio
  42. 6.7.5 Marker Therapeutics, Inc. Recent Developments
  43. 6.8 OncoPep
  44. 6.8.1 OncoPep Company Information
  45. 6.8.2 OncoPep Business Overview
  46. 6.8.3 OncoPep Peptide-Based Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 OncoPep Peptide-Based Vaccines for Cancer Product Portfolio
  48. 6.8.5 OncoPep Recent Developments
  49. 6.9 Sellas Life Sciences
  50. 6.9.1 Sellas Life Sciences Company Information
  51. 6.9.2 Sellas Life Sciences Business Overview
  52. 6.9.3 Sellas Life Sciences Peptide-Based Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Sellas Life Sciences Peptide-Based Vaccines for Cancer Product Portfolio
  54. 6.9.5 Sellas Life Sciences Recent Developments
  55. 6.10 Ultimovacs
  56. 6.10.1 Ultimovacs Company Information
  57. 6.10.2 Ultimovacs Business Overview
  58. 6.10.3 Ultimovacs Peptide-Based Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Ultimovacs Peptide-Based Vaccines for Cancer Product Portfolio
  60. 6.10.5 Ultimovacs Recent Developments
7 North America by Country
  1. 7.1 North America Peptide-Based Vaccines for Cancer Sales by Country
  2. 7.1.1 North America Peptide-Based Vaccines for Cancer Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Peptide-Based Vaccines for Cancer Sales by Country (2021-2026)
  4. 7.1.3 North America Peptide-Based Vaccines for Cancer Sales Forecast by Country (2027-2032)
  5. 7.2 North America Peptide-Based Vaccines for Cancer Market Size by Country
  6. 7.2.1 North America Peptide-Based Vaccines for Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Peptide-Based Vaccines for Cancer Market Size by Country (2021-2026)
  8. 7.2.3 North America Peptide-Based Vaccines for Cancer Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Peptide-Based Vaccines for Cancer Sales by Country
  2. 8.1.1 Europe Peptide-Based Vaccines for Cancer Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Peptide-Based Vaccines for Cancer Sales by Country (2021-2026)
  4. 8.1.3 Europe Peptide-Based Vaccines for Cancer Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Peptide-Based Vaccines for Cancer Market Size by Country
  6. 8.2.1 Europe Peptide-Based Vaccines for Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Peptide-Based Vaccines for Cancer Market Size by Country (2021-2026)
  8. 8.2.3 Europe Peptide-Based Vaccines for Cancer Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Peptide-Based Vaccines for Cancer Sales by Country
  2. 9.1.1 Asia-Pacific Peptide-Based Vaccines for Cancer Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Peptide-Based Vaccines for Cancer Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Peptide-Based Vaccines for Cancer Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Peptide-Based Vaccines for Cancer Market Size by Country
  6. 9.2.1 Asia-Pacific Peptide-Based Vaccines for Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Peptide-Based Vaccines for Cancer Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Peptide-Based Vaccines for Cancer Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Peptide-Based Vaccines for Cancer Sales by Country
  2. 10.1.1 South America Peptide-Based Vaccines for Cancer Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Peptide-Based Vaccines for Cancer Sales by Country (2021-2026)
  4. 10.1.3 South America Peptide-Based Vaccines for Cancer Sales Forecast by Country (2027-2032)
  5. 10.2 South America Peptide-Based Vaccines for Cancer Market Size by Country
  6. 10.2.1 South America Peptide-Based Vaccines for Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Peptide-Based Vaccines for Cancer Market Size by Country (2021-2026)
  8. 10.2.3 South America Peptide-Based Vaccines for Cancer Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Peptide-Based Vaccines for Cancer Sales by Country
  2. 11.1.1 Middle East and Africa Peptide-Based Vaccines for Cancer Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Peptide-Based Vaccines for Cancer Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Peptide-Based Vaccines for Cancer Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Peptide-Based Vaccines for Cancer Market Size by Country
  6. 11.2.1 Middle East and Africa Peptide-Based Vaccines for Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Peptide-Based Vaccines for Cancer Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Peptide-Based Vaccines for Cancer Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Peptide-Based Vaccines for Cancer Value Chain Analysis
  2. 12.1.1 Peptide-Based Vaccines for Cancer Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Peptide-Based Vaccines for Cancer Production Mode & Process
  7. 12.2 Peptide-Based Vaccines for Cancer Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Peptide-Based Vaccines for Cancer Distributors
  10. 12.2.3 Peptide-Based Vaccines for Cancer Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst